Illinois General Assembly - Full Text of Public Act 102-0107
Illinois General Assembly

Previous General Assemblies

Public Act 102-0107


 

Public Act 0107 102ND GENERAL ASSEMBLY

  
  
  

 


 
Public Act 102-0107
 
HB0033 EnrolledLRB102 04106 BMS 14123 b

    AN ACT concerning regulation.
 
    Be it enacted by the People of the State of Illinois,
represented in the General Assembly:
 
    Section 5. The Illinois Insurance Code is amended by
adding Sections 155.47 and 155.48 as follows:
 
    (215 ILCS 5/155.47 new)
    Sec. 155.47. Prohibited practices relating to substance
use disorder treatment.
    (a) As used in this Section, "recovery support",
"substance use disorder", and "treatment" have the meanings
set forth in the Substance Use Disorder Act.
    (b) A company authorized to transact life insurance in
this State may not, based solely on whether an individual has
participated in a substance use treatment or recovery support
program no less than 5 years before application:
        (1) deny coverage to the individual;
        (2) limit the amount, extent, or kind of coverage
    available to the individual; or
        (3) charge the individual or a group to which the
    individual belongs a rate that is different from the rate
    charged to other individuals or groups, respectively, for
    the same coverage, unless the charge is based on sound
    underwriting or actuarial principles reasonably related to
    actual or anticipated loss experience for a particular
    risk.
 
    (215 ILCS 5/155.48 new)
    Sec. 155.48. Prohibited practices relating to prescription
for or obtainment of opioid antagonist.
    (a) As used in this Section, "opioid antagonist" means any
drug that binds to opioid receptors and blocks or otherwise
inhibits the effects of opioids acting on those receptors to
reverse the effects of an opioid overdose.
    (b) A company authorized to transact life insurance in
this State may not, based solely on whether an individual has
been prescribed or has obtained through a standing order an
opioid antagonist:
        (1) deny coverage to the individual;
        (2) limit the amount, extent, or kind of coverage
    available to the individual; or
        (3) charge the individual or a group to which the
    individual belongs a rate that is different from the rate
    charged to other individuals or groups, respectively, for
    the same coverage, unless the charge is based on sound
    underwriting or actuarial principles reasonably related to
    actual or anticipated loss experience for a particular
    risk.

Effective Date: 1/1/2022